These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24623901)

  • 1. Economic benefits of keeping vaccines at ambient temperature during mass vaccination: the case of meningitis A vaccine in Chad.
    Lydon P; Zipursky S; Tevi-Benissan C; Djingarey MH; Gbedonou P; Youssouf BO; Zaffran M
    Bull World Health Organ; 2014 Feb; 92(2):86-92. PubMed ID: 24623901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic evaluation of the controlled temperature chain approach for vaccine logistics: evidence from a study conducted during a meningitis A vaccine campaign in Togo.
    Mvundura M; Lydon P; Gueye A; Diaw IK; Landoh DE; Toi B; Kahn AL; Kristensen D
    Pan Afr Med J; 2017; 27(Suppl 3):27. PubMed ID: 29296162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin.
    Zipursky S; Djingarey MH; Lodjo JC; Olodo L; Tiendrebeogo S; Ronveaux O
    Vaccine; 2014 Mar; 32(13):1431-5. PubMed ID: 24559895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
    Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
    Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential long term vaccine benefits poorly translate in cost effectiveness modelling.
    Black S
    BMJ; 2014 Nov; 349():g6764. PubMed ID: 25394571
    [No Abstract]   [Full Text] [Related]  

  • 7. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.
    Christensen H; Trotter CL; Hickman M; Edmunds WJ
    BMJ; 2014 Oct; 349():g5725. PubMed ID: 25301037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microeconomic evaluation of a mass preventive immunisation campaign against meningococcal meningitis and yellow fever in Senegal in 1997].
    da Silva A; Parent du Châtelet I; Beckr Gaye A; Dompnier JP; Seck I
    Sante; 2003; 13(4):215-23. PubMed ID: 15047438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis.
    Miller MA; Shahab CK
    Pharmacoeconomics; 2005; 23(4):333-43. PubMed ID: 15853434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013.
    Gamougam K; Daugla DM; Toralta J; Ngadoua C; Fermon F; Page AL; Djingarey MH; Caugant DA; Manigart O; Trotter CL; Stuart JM; Greenwood BM
    Emerg Infect Dis; 2015 Jan; 21(1):115-8. PubMed ID: 25536336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.
    La EM; Talbird SE; Kanadanian KV; Huang L; Fain J; Srivastava A
    Hum Vaccin Immunother; 2019; 15(4):978-986. PubMed ID: 30526279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Winter is coming: vaccine negotiations should be concluded swiftly.
    Glennie L; Wright C; Head C
    BMJ; 2014 Nov; 349():g6748. PubMed ID: 25394501
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost effectiveness has its place, but so does common sense.
    Rappuoli R; Wassil J; Bonefeld L; Porter J
    BMJ; 2014 Nov; 349():g6759. PubMed ID: 25394622
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa.
    Miller MA; Wenger J; Rosenstein N; Perkins B
    Pediatr Infect Dis J; 1999 Dec; 18(12):1051-9. PubMed ID: 10608623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of Controlled Temperature Chain (CTC) approach on immunization coverage achieved during the preventive vaccination campaign against meningitis A using MenAfriVac in Togo in 2014].
    Landoh DE; Kahn AL; Lacle A; Adjeoda K; Saka B; Yaya I; Nassoury DI; Kalao A; Makawa MS; Biey NJ; Bita A; Toke YT; Dörte P; Imboua L; Ronveaux O
    Pan Afr Med J; 2017; 27():38. PubMed ID: 28761614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Authors' reply to Rappuoli and colleagues, Black, and Glennie and colleagues.
    Christensen H; Trotter CL; Hickman M; Edmunds WJ
    BMJ; 2014 Nov; 349():g6758. PubMed ID: 25394639
    [No Abstract]   [Full Text] [Related]  

  • 17. Neisseria meningitidis serogroup A vaccines: an overview.
    Vergnano S; Heath P
    Expert Rev Vaccines; 2003 Aug; 2(4):571-82. PubMed ID: 14711341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four years of case-based surveillance of meningitis following the introduction of MenAfriVac in Moissala, Chad: lessons learned.
    Page AL; Coldiron ME; Gamougam K; Acyl MA; Tamadji M; Lastrucci C; Hurtado N; Tehoua FC; Fermon F; Caugant DA; Porten K
    Trop Med Int Health; 2017 Dec; 22(12):1561-1568. PubMed ID: 28992391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation.
    Skull SA; Butler JR; Robinson P; Carnie J
    Int J Epidemiol; 2001 Jun; 30(3):571-8; discussion 578-9. PubMed ID: 11416085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of implementing a demand forecasting system into a low-income country's supply chain.
    Mueller LE; Haidari LA; Wateska AR; Phillips RJ; Schmitz MM; Connor DL; Norman BA; Brown ST; Welling JS; Lee BY
    Vaccine; 2016 Jul; 34(32):3663-9. PubMed ID: 27219341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.